Antisense Makes Financial Sense: Isis-Ortho-McNeil Pact Worth Potential $400 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will co-develop up to four investigational drugs for metabolic diseases, including ISIS 325568 and ISIS 377131 for type 2 diabetes.